

### Product Information

**Size:**

50ul

**Reactivity:**

Human

**Source:**

Rabbit

**Isotype:**

IgG

**Applications:**

ELISA, IHC

**Recommended dilutions:**

ELISA:1:1000-1:2000, IHC:1:25-1:100

**Protein Background:**

E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins.

**Gene ID:**

EPPIN

**Uniprot**

O95925

**Synonyms:**

epididymal peptidase inhibitor

**Immunogen:**


Synthetic peptide of human EPPIN.

**Storage:**


-20&deg; C, pH7.4 PBS, 0.05% NaN<sub>3</sub>, 40% Glycerol

## Product Images

---



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO19612(EPPIN Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: x—200).



The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using PACO19612(EPPIN Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: x—200).